drugset / Trial / NCT00070343

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

NCT00070343

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may help dacarbazine kill more tumor cells by making them more sensitive to the drug. PURPOSE: This clinical trial is studying how well giving oblimersen together with dacarbazine works in treating patients with advanced malignant melanoma that previously responded to treatment with oblimersen and dacarbazine on clinical trial GENTA-GM301.

Timeline

Start
2003-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule Intravenous
Subject oblimersen sodium Antisense oligonucleotide Intravenous

Indications